Clinical management of female patients with Fabry disease based on expert consensus by Eva Brand, Aleš Linhart, Patrick Deegan, Ruxandra Jurcut, Antonio Pisani, Roser Torra, Ulla Feldt-Rasmussen

Get full text

Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey by Ari Zimran, Shoshana Revel-Vilk, Tama Dinur, Majdolen Istaiti, Jaco Botha, Elena Lukina, Pilar Giraldo, Patrick Deegan, Stephan vom Dahl

Get full text

Changes in Angiogenesis and Bone Turnover Markers in Patients with Gaucher Disease Developing Osteonecrosis by Simona D’Amore, Kenneth Eric Poole, Uma Ramaswami, Derralynn Hughes, Kathleen Page, Antonio Giovanni Solimando, Angelo Vacca, Timothy Martin Cox, Patrick Deegan

Get full text

P236: Extending the interval between pegunigalsidase alfa infusions in patients with Fabry disease: Five-year interim results from the ongoing BRIGHT51 study by John Bernat, Myrl Holida, Stephen Waldek, William Wilcox, Nicola Longo, Ozlem Goker-Alpan, Eric Wallace, Patrick Deegan, Camilla Tondel, François Eyskens, Ulla Feldt-Rasmussen, Derralynn Hughes, Antonio Pisani, Ankit Mehta, Khan Nedd, David Warnock, Giovanni Piotti, Meng Wang, Einat Almon-Brill, Sari Alon, Raul Chertkoff, Ales Linhart

Get full text